A Phase 3 interventional study of Ruxolitinib and Placebo in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 112 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-12.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 3rd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
23 studies in Primary Myelofibrosis by Incyte Corporation: 3 open now, 6 under way, none of them phase 3. Of 17 finished, 14 (82%) have results posted.
Among the 23 studies in Primary Myelofibrosis by Incyte Corporation, this one has the largest enrollment of the 22 interventional ones that give a count, is the only one that started in 2009, is one of 3 in phase 3, and was the 2nd registered.
Incyte Corporation’s Primary Myelofibrosis studies by the year they started, since 2007.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Incyte Corporation’s 23 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).
Patients with spleen growth of greater than 25% based on an increase in spleen volume from Baseline were eligible for early unblinding, and for patients on placebo, cross over to ruxolitinib prior to the primary study endpoint being reached. If this spleen growth occurred before Week 24, it must have been accompanied by specific worsening of symptoms, based on worsening early satiety accompanied by weight loss or worsening pain requiring daily narcotic use. After Week 24, asymptomatic spleen growth alone was sufficient for early unblinding and potential cross over. Patients found to have been randomized to ruxolitinib after early unblinding prior to Week 24 were discontinued.
When half of the patients remaining in the study completed the Week 36 visit and all patients enrolled completed Week 24 or discontinued, the database was frozen and the primary analysis was conducted. Once this was complete, all patients were unblinded and patients who had been randomized to placebo were given the opportunity to cross over to ruxolitinib treatment, provided hematology laboratory parameters were adequate; Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
This study's enrollment of 309 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Browse Primary Myelofibrosis studies →Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Compared within Primary Myelofibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myeloproliferative Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
Drug: Ruxolitinib
Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
Drug: Ruxolitinib · Drug: Placebo
Ruxolitinib phosphate tablets 5 mg administered as oral doses.
Also known as: INCB018424
Matching placebo tablets were administered as oral doses in the same manner as active drug.
Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24
Spleen volume was assessed by magnetic resonance imaging (MRI) or by computed tomography (CT) scans if MRI was not suitable, and analyzed by a blinded central laboratory reader. Patients who withdrew, crossed over to ruxolitinib prior to the visit, or had a missing value at the visit were considered non-responders.
Time frame: Baseline and Week 24
Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.
Time frame: Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
The duration of ≥ 35% reduction from Baseline in spleen volume was defined as the longest duration of consecutive measurements of ≥ 35% reduction observed before the data cut-off date for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or, who subsequently dropped out prior to another assessment. The duration of a ≥ 35% reduction from Baseline in spleen volume was analyzed using the Kaplan-Meier method.
Time frame: Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
Time frame: Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.
Change From Baseline to Week 24 in Total Symptom Score
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms hence a negative change from baseline indicates improvement.
Time frame: Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.
Overall Survival
Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
Time frame: From randomization to the data cut-off date (up to 14 months).
Overall Survival Time
Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
Time frame: From randomization to the data cut-off date (up to 14 months).
Overall Survival - Extended Data
Overall survival is reported here by the number of deaths from randomization until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.
Time frame: From randomization to 4 months after the data cut-off date (up to 18 months).
Overall Survival Time - Extended Data
Overall survival was assessed by the time to death or censoring up until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.
Time frame: From randomization to 4 months after the data cut-off date (up to 18 months).
Overall Survival at Week 144
Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.
Time frame: Week 144
Overall Survival Time at Week 144
Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.
Time frame: Week 144
| Milestone | Ruxolitinib | Placebo |
|---|---|---|
| Started | 155 | 154 |
| Safety population | 155 | 151 |
| Completed | 134 | 114 |
| Not completed | 21 | 40 |
| Withdrew: Death | 9 | 9 |
| Withdrew: Adverse event | 8 | 8 |
| Withdrew: Disease progression | 3 | 12 |
| Withdrew: Withdrawal by subject | 1 | 10 |
| Withdrew: Data lost during site relocation | 0 | 1 |
| Milestone | Ruxolitinib | Placebo |
|---|---|---|
| Started | 0 | 111 |
| Completed | 0 | 57 |
| Not completed | 0 | 54 |
| Withdrew: Adverse event | 0 | 19 |
| Withdrew: Disease progression | 0 | 15 |
| Withdrew: Withdrawal by subject | 0 | 11 |
| Withdrew: Non-compliance to study medication | 0 | 2 |
| Withdrew: Other unspecified | 0 | 7 |
Spleen volume was assessed by magnetic resonance imaging (MRI) or by computed tomography (CT) scans if MRI was not suitable, and analyzed by a blinded central laboratory reader. Patients who withdrew, crossed over to ruxolitinib prior to the visit, or had a missing value at the visit were considered non-responders.
| participants | Ruxolitinib | Placebo |
|---|---|---|
| Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 | 65 | 1 |
The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.
| proportion of participants | Ruxolitinib |
|---|---|
| Still Responder by 48 weeks | 0.76 (0.66 to 0.84) |
| Still Responder by 96 weeks | 0.67 (0.55 to 0.76) |
| Still Responder by 144 weeks | 0.27 (0.02 to 0.63) |
The duration of ≥ 35% reduction from Baseline in spleen volume was defined as the longest duration of consecutive measurements of ≥ 35% reduction observed before the data cut-off date for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or, who subsequently dropped out prior to another assessment. The duration of a ≥ 35% reduction from Baseline in spleen volume was analyzed using the Kaplan-Meier method.
| weeks | Ruxolitinib |
|---|---|
| Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib | 135.0 (107.6 to NA) |
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.
| participants | Ruxolitinib | Placebo |
|---|---|---|
| Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24 | 68 | 8 |
Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms hence a negative change from baseline indicates improvement.
| scores on a scale | Ruxolitinib | Placebo |
|---|---|---|
| Baseline | 18.0 ± 10.9 | 16.5 ± 11.5 |
| Week 24 | 9.4 ± 9.7 | 19.7 ± 13.7 |
| Change from Baseline | -8.6 ± 10.0 | 3.2 ± 9.4 |
Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
| participants | Ruxolitinib | Placebo |
|---|---|---|
| Death events | 10 | 14 |
| Censored events | 145 | 140 |
Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
| weeks | Ruxolitinib | Placebo |
|---|---|---|
| Overall Survival Time | NA (NA to NA) | NA (NA to NA) |
Overall survival is reported here by the number of deaths from randomization until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.
| participants | Ruxolitinib | Placebo |
|---|---|---|
| Death events | 13 | 24 |
| Censored events | 142 | 130 |
Overall survival was assessed by the time to death or censoring up until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.
| weeks | Ruxolitinib | Placebo |
|---|---|---|
| Overall Survival Time - Extended Data | NA (NA to NA) | NA (NA to NA) |
Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.
| participants | Ruxolitinib | Placebo |
|---|---|---|
| Death events | 42 | 54 |
| Censored events | 113 | 100 |
Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.
| probability | Ruxolitinib | Placebo |
|---|---|---|
| Overall Survival Time at Week 144 | 0.74 (0.66 to 0.81) | 0.61 (0.53 to 0.69) |
Collected over From randomization through data cut-off of the primary analysis (02 November 2010).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | — | 43/155 (27.7%) | 150/155 (96.8%) |
| Placebo | — | 53/151 (35.1%) | 147/151 (97.4%) |
| Event | Ruxolitinib | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 10/155 | 5/151 |
| Abdominal painGastrointestinal disorders | 0/155 | 6/151 |
| AnaemiaBlood and lymphatic system disorders | 5/155 | 3/151 |
| Splenic infarctionBlood and lymphatic system disorders | 1/155 | 4/151 |
| FatigueGeneral disorders | 4/155 | 0/151 |
| Cardiac failure congestiveCardiac disorders | 1/155 | 3/151 |
| Disease progressionGeneral disorders | 0/155 | 3/151 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/155 | 3/151 |
| ColitisGastrointestinal disorders | 1/155 | 3/151 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/155 | 1/151 |
| Event | Ruxolitinib | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 16/155 | 58/151 |
| FatigueGeneral disorders | 38/155 | 51/151 |
| ThrombocytopeniaBlood and lymphatic system disorders | 52/155 | 14/151 |
| AnaemiaBlood and lymphatic system disorders | 45/155 | 20/151 |
| DiarrhoeaGastrointestinal disorders | 36/155 | 32/151 |
| Oedema peripheralGeneral disorders | 29/155 | 34/151 |
| NauseaGastrointestinal disorders | 22/155 | 29/151 |
| EcchymosisSkin and subcutaneous tissue disorders | 29/155 | 14/151 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 26/155 | 25/151 |
| PruritusSkin and subcutaneous tissue disorders | 7/155 | 23/151 |
| Age, Continuous(years) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Mean | 66.7 ± 8.82 | 68.7 ± 8.66 | 67.7 ± 8.78 |
| Sex/Gender, Customized(participants) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Female | 76 | 65 | 141 |
| Male | 79 | 88 | 167 |
| Race/Ethnicity, Customized(participants) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Black or African American | 6 | 7 | 13 |
| White | 138 | 139 | 277 |
| Asian | 5 | 4 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 5 | 3 | 8 |
| Disease Subtype(participants) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Primary myelofibrosis | 70 | 84 | 154 |
| Post-polycythemia vera-myelofibrosis | 50 | 47 | 97 |
| Post-essential thrombocythemia-myelofibrosis | 35 | 22 | 57 |
| Missing | 0 | 1 | 1 |
| Spleen volume(cm˄3) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Mean | 2745.7 ± 1247.0 | 2797.6 ± 1388.5 | 2771.5 ± 1317.3 |
| JAK2 V617F Mutation Status(participants) | Ruxolitinib | Placebo | Total |
|---|---|---|---|
| Positive | 113 | 123 | 236 |
| Negative | 40 | 27 | 67 |
| Unknown/Missing | 2 | 4 | 6 |
Showing the first 100 of 112 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2009, a primary completion of Nov 2010 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 2 months after primary completion. A results delay was requested in Jun 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib